首页|糖化血红蛋白、β2-微球蛋白检测在糖尿病患者中的应用价值分析

糖化血红蛋白、β2-微球蛋白检测在糖尿病患者中的应用价值分析

扫码查看
目的 分析糖化血红蛋白、β2-微球蛋白检测对糖尿病患者的临床价值。方法 选取70例糖尿病患者和同期70例健康人员分别作为研究组和对照组。对所有受试者糖化血红蛋白、β2-微球蛋白、空腹血糖进行检测,比较两组糖化血红蛋白、β2-微球蛋白、空腹血糖水平以及研究组不同病程患者的糖化血红蛋白、β2-微球蛋白水平,比较两组 β2-微球蛋白阳性率。结果 研究组的糖化血红蛋白(8。558±1。942)%、β2-微球蛋白(9。140±1。269)mg/L、空腹血糖(10。160±2。725)mmol/L与对照组的(5。501±0。329)%、(2。340±1。069)mg/L、(5。103±0。632)mmol/L比较均升高(P<0。05)。研究组病程<5年、5~10年患者的糖化血红蛋白、β2-微球蛋白水平比较无差异(P>0。05);病程>10年患者的糖化血红蛋白(11。124±3。630)%、β2-微球蛋白(10。500±1。496)mg/L与病程<5年的(7。882±2。483)%、(8。923±0。773)mg/L以及5~10年的(9。126±2。827)%、(9。216±1。014)mg/L比较均升高(P<0。05)。研究组β2-微球蛋白阳性率95。71%与对照组的8。57%比较更高(P<0。05)。结论 对糖尿病患者进行β2-微球蛋白水平与糖化血红蛋白水平检测,能对患者近期内的血糖情况进行详细分析,有利于药物治疗方案的调整。且β2-微球蛋白水平也能有效评估患者的肾脏微血管病变情况,对糖尿病肾病的诊断具有重要作用,能达到尽早诊断、尽早治疗的目的。
Analysis of the application value of glycosylated hemoglobin and β2-microglobulin tests in diabetic patients
Objective To analyze the clinical value of glycosylated hemoglobin and β2-microglobulin tests in diabetic patients. Methods 70 diabetic patients and 70 healthy subjects were selected and set as the study group and the control group. Glycosylated hemoglobin,β2-microglobulin,and fasting blood glucose were tested in all subjects,and the levels of glycosylated hemoglobin,β2-microglobulin,and fasting blood glucose were compared between the two groups;the levels of glycosylated hemoglobin and β2-microglobulin were compared among patients with different disease duration in the study group;the positive rate of β2-microglobulin was compared between the two groups. Results In the study group,the glycosylated hemoglobin was (8.558±1.942)%,the β2-microglobulin was (9.140±1.269) mg/L,and the fasting blood glucose was (10.160±2.725) mmol/L,which were higher than (5.501±0.329)%,(2.340±1.069) mg/L,and (5.103±0.632) mmol/L in the control group (P<0.05). There was no difference in the comparison of glycosylated hemoglobin and β2-microglobulin levels between patients with a disease duration of<5 years and 5-10 years in the study group (P>0.05). The glycosylated hemoglobin of patients with a disease duration of>10 years was (11.124±3.630)% and the β2-microglobulin was (10.500±1.496) mg/L,which were higher than (7.882±2.483)% and (8.923±0.773) mg/L of patients with a disease duration of<5 years,and (9.126±2.827)% and (9.216±1.014) mg/L of patients with a disease duration of 5-10 years (P<0.05). The positive rate of β2-microglobulin of 95.71% in the study group was higher than 8.57% in the control group (P<0.05). Conclusion For diabetic patients,the glycosylated hemoglobin and β2-microglobulin test can analyze the recent blood glucose situation of patients in detail,which is conducive to the adjustment of drug treatment plan. In addition,β2-microglobulin level can also effectively evaluate the renal microangiopathy of patients,which plays an important role in the diagnosis of diabetic nephropathy,and can achieve the effect of early diagnosis and treatment.

Glycosylated hemoglobinβ2-microglobulinDiabetesBlood glucose changesFasting blood glucose

王善刚、李海英、宋康康

展开 >

256603 滨州医学院附属医院检验科

糖化血红蛋白 β2-微球蛋白 糖尿病 血糖变化 空腹血糖

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(23)